JE00BYSS4X48
JE00BYSS4X48
NovoCure Limited
Loading chart...
Company Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Latest News

Simply Wall St. • 16h ago
The Bull Case For NovoCure (NVCR) Could Change Following Japan’s Optune Pax Pancreatic Cancer Approval

Business Wire • 10/01/2026
Novocure to Report Third Quarter 2026 Financial Results

Simply Wall St. • 09/23/2026
NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall

Simply Wall St. • 09/23/2026
NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change

MarketBeat • 09/18/2026
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
Company Profile
5
MetricsCountry
Region
Sector
Industry
Website
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
7/7 Very High
5Y Volatility
81.4% p.a.
Max Drawdown (5Y)
-91.8%
Sharpe Ratio (5Y)
-0.45
Beta Factor
0.99
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (81.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -95.5% in the extended horizon.